TABLE 3.

Trends in antimicrobial resistance among various GNB between 1993 and 2004a

OrganismAntimicrobial% of isolates (%I/%R)Trendb
1993-19951996-19981999-20012002-2004
Pseudomonas aeruginosaCeftazidime5.6/9.95.6/125.2/14.26.3/4.5
Imipenem4.5/10.63.5/11.13.6/13.73.8/14.5
Tobramycin0.9/7.81.5/9.60.4/13.31.8/13.7
Ciprofloxacin5.6/11.25.7/17.65.4/25.14.8/28.9
Escherichia coliAmpicillin-sulbactam10/22.910.8/26.410.3/28.613.5/30
Ceftriaxone0.8/11.3/2.31.6/2.72.1/4.6
Tobramycin0.9/1.50.1/2.91/4.63.3/7.1
Ciprofloxacin0.2/0.90.4/3.90.4/8.30.2/17.3
Klebsiella pneumoniaeCeftazidime0.6/12.71.4/13.51/10.80.8/3.8
Piperacillin27.4/38.322.3/36.922.1/37.417/28.7
Ciprofloxacin3.1/7.93.4/9.71.8/10.51.4/16.8
Enterobacter cloacaeCeftazidime3.9/364.2/33.83.6/30.42.7/11.7
Ciprofloxacin2.5/52.9/7.62.1/10.91.7/12.4
Acinetobacter spp.aAmpicillin-sulbactam6/18.29.3/227.5/25.58.1/33.2
Ceftriaxone25/30.121.3/4316.3/51.716.2/56.2
Ceftazidime10.1/23.98.7/36.88/45.28.2/14.6
Cefepime13.7/31.615.5/37.714.2/49
Piperacillin18.9/31.416.4/40.314.8/49.110.9/52.4
Piperacillin-tazobactam22.4/18.420.1/26.717.9/36.9
Imipenem2.1/24.4/2.16.6/5.66.9/5.2
Tobramycin7.8/137/24.55.8/30.45.2/30.3
Amikacin3.7/5.73.9/13.44.1/19.25/23.9
Ciprofloxacin2.6/35.93/49.41.9/57.11/63.8
Serratia marcescensCeftazidime1.8/8.43.5/11.62.5/10.72.2/1.9
Imipenem2.8/3.61.5/1.80.7/1.30.1/0.7
Enterobacter aerogenesCeftazidime6.3/23.83/24.73.5/22.75.9/4.6
Piperacillin12.5/2215.8/17.111.5/19.511.3/10.8
Proteus mirabilisImipenem7.7/3.42.8/1.21.1/1.20.7/0
Ciprofloxacin0.3/3.32.1/7.80.1/13.12.1/15
Klebsiella oxytocaCefepime0.9/3.41.9/5.11.1/2
Citrobacter freundiiCeftazidime1.9/43.61.5/473.1/38.93.9/15
Ertapenem1.4/1.70.4/3.9
Tobramycin2.2/10.85.3/12.73.4/12.73.9/23.1
Ciprofloxacin2.8/9.24.7/14.43.4/14.94.7/21.4
  • a I, intermediate; R, resistant.

  • b Increase (↑) or decrease (↓) in resistance in the 12-year study period.